During the past decade, Centre Claudius Regaud conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 1 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Centre Claudius Regaud" #1 sponsor was "ARCAGY/ GINECO GROUP" with 4 trials, followed by "Centre Oscar Lambret" with 2 trials sponsored, "Hospira, now a wholly owned subsidiary of Pfizer" with 2 trials sponsored, "National Cancer Institute (NCI)" with 2 trials sponsored and "AGO Study Group" with 2 trials sponsored. Other sponsors include 2 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Centre Claudius Regaud" #1 collaborator was "Cancer Research UK" with 2 trials as a collaborator, "ARCAGY/ GINECO GROUP" with 1 trials as a collaborator, "Centre Georges Francois Leclerc" with 1 trials as a collaborator, "European Organisation for Research and Treatment of Cancer - EORTC" with 1 trials as a collaborator and "Grupo Español de Investigación en Cáncer de Ovario" with 1 trials as a collaborator. Other collaborators include 1 different institutions and companies that were collaborators in the rest 11 trials.

According to Clinical.Site data, the most researched conditions in "Centre Claudius Regaud" are "Breast Cancer" (3 trials), "Cervix Cancer" (2 trials), "Ovarian Cancer" (2 trials), "Solid Tumors" (2 trials) and "All Solid Tumors" (1 trials). Many other conditions were trialed in "Centre Claudius Regaud" in a lesser frequency.

Most popular intervention types in "Centre Claudius Regaud" are "Drug" (11 trials), "Procedure" (3 trials), "Other" (2 trials), "Behavioral" (1 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (2 trials), "Anastrozole" (1 trials), "BKM120" (1 trials), "Cabozantinib S-malate" (1 trials) and "Cisplatin" (1 trials). Other intervention names were less common.

The vast majority of trials in "Centre Claudius Regaud" are 11 trials for "Female" genders, 6 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Centre Claudius Regaud". undefined are not yet recruiting, undefined are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 12 completed trials in Centre Claudius Regaud, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Centre Claudius Regaud, 2 "Phase 1" clinical trials were conducted, 9 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 2 trials that are defined as “Not Applicable".